内生性增长成主导复星医药2005年中报显示,公司实现主营收入14.67亿元,同比增长14.29%;主营业务利润4.6亿元,同比增长21.77%;净利润1.21亿元,同比略微下降。收入增长的主要原因在于医药工业增长明显,而净利润下降的原因在于复地的投资收益出现下降。自2003年以来,来自医药主业 Endogenous growth led Fosun Pharma 2005 mid-year report shows that the company achieved 1.467 billion yuan main income, an increase of 14.29%; main business profit 460 million yuan, an increase of 21.77%; net profit of 121 million yuan, a slight decline . The main reason for the increase in revenue was the obvious growth of the pharmaceutical industry. The reason for the decrease in net profit was the decrease in the return on investment from Forte. Since 2003, from the main pharmaceutical industry